{"id":717,"date":"2026-05-22T22:08:52","date_gmt":"2026-05-23T02:08:52","guid":{"rendered":"https:\/\/www.durhampeptides.ca\/post\/cjc-1295-vs-ipamorelin"},"modified":"2026-06-22T14:22:28","modified_gmt":"2026-06-22T18:22:28","slug":"cjc-1295-vs-ipamorelin","status":"publish","type":"post","link":"https:\/\/www.durhampeptides.ca\/fr\/post\/cjc-1295-vs-ipamorelin","title":{"rendered":"CJC-1295 vs Ipamorelin: Why Researchers Combine Them"},"content":{"rendered":"<figure><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-199\" src=\"https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/CJC-1295No-DAC-IPAMORELIN-10MG.png\" alt=\"CJC-1295 vs Ipamorelin GHRH analog ghrelin agonist comparison Durham Peptides Canada\" width=\"1024\" height=\"1535\" srcset=\"https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/CJC-1295No-DAC-IPAMORELIN-10MG.png 1024w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/CJC-1295No-DAC-IPAMORELIN-10MG-200x300.webp 200w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/CJC-1295No-DAC-IPAMORELIN-10MG-683x1024.webp 683w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/CJC-1295No-DAC-IPAMORELIN-10MG-768x1151.webp 768w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/CJC-1295No-DAC-IPAMORELIN-10MG-800x1199.webp 800w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<p>CJC-1295 vs Ipamorelin GHRH analog ghrelin agonist comparison Durham Peptides Canada<\/p>\n<p><\/p>\n<p>\"CJC-1295 vs Ipamorelin\" is a common search, but it frames the two compounds as competitors when, in research practice, they're collaborators. They act on different receptors, through different pathways, with different effects on the growth-hormone pulse \u2014 which is precisely why they're so often studied <em>together<\/em> rather than chosen one over the other. Understanding the difference between them is the key to understanding why the combination is studied at all.<\/p>\n<p><\/p>\n<p>This article compares the two compounds directly: what each is, how their mechanisms differ, and the research logic of pairing them. For the blend itself, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/cjc-1295-ipamorelin-blend-explained\/\" target=\"_blank\">CJC-1295 + Ipamorelin Blend Explained<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>The Fundamental Difference: Two Different Receptors<\/strong><\/p>\n<p><\/p>\n<p>The single most important distinction is which receptor each compound targets:<\/p>\n<ul><li><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-no-dac-10mg\/\" target=\"_blank\"><strong>CJC-1295 (No DAC)<\/strong><\/a><\/u> is a GHRH analog. It binds the <strong>GHRH receptor<\/strong> on pituitary somatotrophs and stimulates the synthesis and release of growth hormone.<\/li><li><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/ipamorelin-10mg\/\" target=\"_blank\"><strong>Ipamorelin<\/strong><\/a><\/u> is a ghrelin mimetic. It binds the <strong>GHS-R1a (ghrelin) receptor<\/strong> and amplifies the amplitude of growth-hormone pulses.<\/li><\/ul>\n<p><\/p>\n<p>These are genuinely different molecular targets engaging different intracellular signaling. That non-overlap is the foundation of everything else.<\/p>\n<p><\/p>\n<p><strong>Side-by-Side Comparison<\/strong><\/p>\n<table><tr><td><p>Property<\/p><\/td><td><p>CJC-1295 (No DAC)<\/p><\/td><td><p>Ipamorelin<\/p><\/td><\/tr><tr><td><p>Class<\/p><\/td><td><p>GHRH analog<\/p><\/td><td><p>Selective GHS \/ ghrelin-receptor agonist<\/p><\/td><\/tr><tr><td><p>Receptor<\/p><\/td><td><p>GHRH receptor<\/p><\/td><td><p>GHS-R1a (ghrelin) receptor<\/p><\/td><\/tr><tr><td><p>Format<\/p><\/td><td><p>30 amino acids<\/p><\/td><td><p>5 amino acids (pentapeptide)<\/p><\/td><\/tr><tr><td><p>Molecular weight<\/p><\/td><td><p>3367.9 g\/mol<\/p><\/td><td><p>711.85 g\/mol<\/p><\/td><\/tr><tr><td><p>CAS number<\/p><\/td><td><p>446036-97-1<\/p><\/td><td><p>170851-70-4<\/p><\/td><\/tr><tr><td><p>Primary research effect<\/p><\/td><td><p>Stimulates GH synthesis\/release<\/p><\/td><td><p>Amplifies GH pulse amplitude<\/p><\/td><\/tr><tr><td><p>Half-life (No DAC form)<\/p><\/td><td><p>Short (minutes)<\/p><\/td><td><p>Short (minutes)<\/p><\/td><\/tr><tr><td><p>Effect on cortisol\/prolactin<\/p><\/td><td><p>Minimal<\/p><\/td><td><p>Minimal (selective)<\/p><\/td><\/tr><\/table>\n<p><strong>How Their Mechanisms Differ<\/strong><\/p>\n<p><\/p>\n<p><strong>CJC-1295 (No DAC)<\/strong> works \"upstream,\" mimicking the body's own GHRH signal. It tells the somatotrophs to produce and release growth hormone. As a GHRH analog, its effect is gated by somatostatin (the inhibitory counter-signal), so it works within the body's natural regulatory feedback.<\/p>\n<p><\/p>\n<p><strong>Ipamorelin<\/strong> works through a separate channel entirely. As a ghrelin-receptor agonist, it both stimulates GH release and suppresses somatostatin tone, and it's studied for increasing the <em>amplitude<\/em> of GH pulses. Its selectivity is its signature trait \u2014 unlike older GHRPs (GHRP-6, GHRP-2), it produces GH release with minimal cortisol or prolactin effects, making it a cleaner research tool.<\/p>\n<p><\/p>\n<p><strong>Why the Difference Creates Synergy<\/strong><\/p>\n<p><\/p>\n<p>Because the two compounds engage GH release through separate, complementary mechanisms, activating both at once is studied for a synergistic effect \u2014 a combined GH response greater than the sum of either alone. The classic model:<\/p>\n<ul><li>CJC-1295 raises the <em>baseline drive<\/em> for GH synthesis and release (GHRH pathway).<\/li><li>Ipamorelin <em>amplifies the pulse<\/em> and reduces inhibitory tone (ghrelin pathway).<\/li><\/ul>\n<p><\/p>\n<p>Together, they push the same output (GH release) through two independent inputs. This GHRH-analog-plus-ghrelin-mimetic synergy is well documented across the secretagogue literature and is the reason the two are combined in Durham Peptides' <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-ipamorelin-blend-10mg\/\" target=\"_blank\">CJC-1295 (No DAC) + Ipamorelin Blend<\/a><\/u>. For the broader category framing, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/growth-hormone-secretagogues-explained\/\" target=\"_blank\">Growth Hormone Secretagogues Explained<\/a><\/u>.<\/p>\n<p><\/p>\n<p>This is the same compositional logic that underlies other studied combinations in the Durham Peptides catalog \u2014 pairing compounds with distinct, complementary mechanisms rather than redundant ones. The <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/wolverine-stack-explained\/\" target=\"_blank\">Wolverine Stack<\/a><\/u> (BPC-157 + TB-500) follows the same principle in the tissue-repair category.<\/p>\n<p><\/p>\n<p><strong>When You'd Choose One Over the Other<\/strong><\/p>\n<p><\/p>\n<p>Despite the synergy story, there are research reasons to use a single compound:<\/p>\n<ul><li><strong>Study the GHRH pathway in isolation<\/strong> \u2192 CJC-1295 (No DAC) alone.<\/li><li><strong>Study the ghrelin\/GHS pathway in isolation<\/strong> \u2192 Ipamorelin alone.<\/li><li><strong>Study the combined, synergistic effect<\/strong> \u2192 the blend, or both compounds together.<\/li><\/ul>\n<p><\/p>\n<p>So the honest answer to \"CJC-1295 vs Ipamorelin\" is that it's rarely an either\/or in combination research \u2014 but for mechanistic isolation work, the choice depends entirely on which pathway is under study.<\/p>\n<p><\/p>\n<p><strong>Questions fr\u00e9quentes<\/strong><\/p>\n<p><\/p>\n<p><strong>What's the difference between CJC-1295 and Ipamorelin?<\/strong> CJC-1295 (No DAC) is a GHRH analog acting on the GHRH receptor to stimulate GH synthesis\/release; Ipamorelin is a selective ghrelin-receptor agonist that amplifies GH pulse amplitude. Different receptors, different mechanisms.<\/p>\n<p><\/p>\n<p><strong>Why are CJC-1295 and Ipamorelin combined?<\/strong> Because they engage GH release through complementary, non-overlapping pathways, the combination is studied for synergistic GH elevation greater than either alone.<\/p>\n<p><\/p>\n<p><strong>Is CJC-1295 or Ipamorelin better?<\/strong> Neither is universally \"better\" \u2014 they do different <\/p>\n<p>things. For combination research they're used together; for mechanistic isolation, the choice depends on which pathway is being studied.<\/p>\n<p><\/p>\n<p><strong>Does Ipamorelin raise cortisol like other GHRPs?<\/strong> No. Ipamorelin is characterized as selective, producing GH release with minimal cortisol and prolactin effects, unlike GHRP-6 and GHRP-2.<\/p>\n<p><\/p>\n<p><strong>Can I buy them individually?<\/strong> Yes. Durham Peptides stocks <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-no-dac-10mg\/\" target=\"_blank\">CJC-1295 (No DAC)<\/a><\/u> et <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/ipamorelin-10mg\/\" target=\"_blank\">Ipamorelin<\/a><\/u> separately, plus the <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-ipamorelin-blend-10mg\/\" target=\"_blank\">combined blend<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>Do they both have short half-lives?<\/strong> Yes \u2014 CJC-1295 No DAC and Ipamorelin both have short half-lives, which preserves the natural pulsatile pattern of GH secretion.<\/p>\n<p><\/p>\n<p><strong>Final Thoughts<\/strong><\/p>\n<p><\/p>\n<p>CJC-1295 and Ipamorelin aren't rivals \u2014 they're two halves of a dual-pathway approach to growth-hormone research, each engaging a different receptor to push the same output. That's why \"vs\" is the wrong frame for combination work, and why the <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-ipamorelin-blend-10mg\/\" target=\"_blank\">blend<\/a><\/u> exists.<\/p>\n<p>For the full mechanism, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/cjc-1295-ipamorelin-blend-explained\/\" target=\"_blank\">CJC-1295 + Ipamorelin Blend Explained<\/a><\/u>; for the category, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/growth-hormone-secretagogues-explained\/\" target=\"_blank\">Growth Hormone Secretagogues Explained<\/a><\/u>; and for buying, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/buy-cjc-1295-ipamorelin-canada\/\" target=\"_blank\">Buy CJC-1295 + Ipamorelin in Canada<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>Selected Research References<\/strong><\/p>\n<p><\/p>\n<ol><li>Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the First Selective Growth Hormone Secretagogue. <em>European Journal of Endocrinology<\/em>. 1998;139(5):552-561. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9849822\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/9849822\/<\/a><\/u><\/li><li>Teichman SL, Neale A, Lawrence B, et al. Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GHRH. <em>Journal of Clinical Endocrinology &amp; Metabolism<\/em>. 2006;91(3):799-805. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16352683\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/16352683\/<\/a><\/u><\/li><li>Bowers CY, Momany FA, Reynolds GA, Hong A. On the In Vitro and In Vivo Activity of a New Synthetic Hexapeptide That Acts on the Pituitary to Specifically Release Growth Hormone. <em>Endocrinology<\/em>. 1984. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/1349865\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/1349865\/<\/a><\/u><\/li><\/ol>\n<p><\/p>\n<p><em>All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.<\/em><\/p>","protected":false},"excerpt":{"rendered":"CJC-1295 vs Ipamorelin GHRH analog ghrelin agonist comparison Durham Peptides Canada \"CJC-1295 vs Ipamorelin\" is a common search, but it frames the two compounds as competitors when, in research practice, they're collaborators. They act on different receptors, through different pathways, with different effects on the growth-hormone pulse \u2014 which is precisely why they're so often studied together rather than chosen one over the other. Understanding the difference between them is the key to...","protected":false},"author":1,"featured_media":205,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"class_list":["post-717","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-science"],"_links":{"self":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/717","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/comments?post=717"}],"version-history":[{"count":1,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/717\/revisions"}],"predecessor-version":[{"id":1058,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/717\/revisions\/1058"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media\/205"}],"wp:attachment":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media?parent=717"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/categories?post=717"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/tags?post=717"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}